Welcome to our dedicated page for Trulieve Cannabis SEC filings (Ticker: TCNNF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Trulieve Cannabis Corp. (TCNNF) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and periodic financial statements. As a British Columbia–incorporated issuer with operations in the United States, Trulieve files with the Securities and Exchange Commission, offering detailed insight into its financial condition, capital structure, and material events.
Trulieve’s recent Form 8-K filings illustrate how the company uses SEC reports to communicate significant developments. For example, the company has filed 8-Ks describing commitments for, and the issuance of, 10.5% senior secured notes due 2030, including key terms such as interest rate, maturity, security (a pledge of shares of a restricted subsidiary), optional redemption provisions, and covenants that limit additional indebtedness, restricted payments, asset sales, and affiliate transactions. These filings also explain that net proceeds are intended for capital expenditures and general corporate purposes.
Other 8-Ks cover topics such as the redemption and planned delisting of 8.0% senior secured notes due 2026, and the release of quarterly financial results. In these documents, Trulieve reports revenue, gross profit, net loss, cash flow from operations, and non-GAAP measures, along with condensed balance sheets and cash flow statements. Investors can use these filings to analyze trends in retail revenue, operating expenses, leverage, and liquidity.
Through Stock Titan, users can view Trulieve’s 10-Q and 10-K filings when available, which provide more comprehensive discussions of risk factors, tax matters (including Section 280E and uncertain tax positions), and segment performance. The platform’s AI-powered summaries help explain complex sections, such as debt indentures, covenant packages, and non-GAAP reconciliations, so readers can quickly grasp what changes in each filing may mean for Trulieve’s operations and capital structure. Real-time updates ensure that new Forms 4, 8-K, 10-Q, and 10-K are surfaced as they are posted to EDGAR.
Trulieve Cannabis Corp. director Matthew J. Foulston reported an award of 23,438 subordinate voting shares in the form of restricted stock units. These RSUs were granted at no cash cost as equity compensation and increase his direct holdings to 34,767 shares after the transaction.
The footnote explains that each RSU converts into one subordinate voting share, vesting on the earliest of his service ending on the board, a change of control of Trulieve, or December 1, 2032. This is a routine compensation-related equity grant rather than an open-market purchase or sale.
Morreau Jane Cecil reported acquisition or exercise transactions in this Form 4 filing.
Trulieve Cannabis Corp. director Jane Cecil Morreau reported an award of 23,438 Subordinate Voting Shares on 2026-03-13, recorded at $0.00 per share, bringing her reported direct holdings to 65,778 shares.
According to the footnote, this represents a grant of restricted stock units (RSUs), each equal to one Trulieve subordinate voting share. The RSUs will vest on the earliest of the end of her board service, a change of control of Trulieve, or December 1, 2032.
Trulieve Cannabis Corp. director Richard S. May reported an equity compensation grant of 23,438 restricted stock units (RSUs) tied to the company’s subordinate voting shares. The award was recorded at no cash purchase price, reflecting a compensation-related, not open-market, acquisition.
Each RSU represents the right to receive one subordinate voting share. The RSUs will vest on the earliest of the end of May’s board service, a change of control of Trulieve, or December 1, 2032. Following this grant, May directly holds 593,534 subordinate voting shares.
Healy Peter reported acquisition or exercise transactions in this Form 4 filing.
Trulieve Cannabis Corp. director Peter Healy reported an equity compensation grant in the form of restricted stock units (RSUs) covering 23,438 subordinate voting shares. The award was recorded at a price of $0.00 per unit, reflecting a grant rather than a market purchase. Following this grant, Healy is shown as holding 72,673 subordinate voting shares. Each RSU represents a contingent right to receive one Trulieve subordinate voting share and will vest on the earliest of the end of Healy’s board service, a change of control of Trulieve, or December 1, 2032.
Beshears Thad reported acquisition or exercise transactions in this Form 4 filing.
Trulieve Cannabis Corp. director Beshears Thad received an award of 23,438 restricted stock units (RSUs) tied to Subordinate Voting Shares. The grant was reported at a price of zero, indicating a compensation-related award rather than an open‑market purchase.
Each RSU represents the right to receive one Trulieve subordinate voting share. The RSUs will vest on the earliest of the end of his board service, a change of control of Trulieve, or December 1, 2032. After this grant, he directly holds 2,487,043 Subordinate Voting Shares. He also directly holds 15,000 Multiple Voting Shares, which are convertible on a one‑for‑100 basis into an aggregate of 1,500,000 Subordinate Voting Shares.
Trulieve Cannabis Corp. filed an initial insider report for Chief Accounting Officer Brett R. Walsh, detailing his existing equity position. He directly holds 111,594 subordinate voting shares and a stock option to buy 7,160 subordinate voting shares at an exercise price of $21.48 per share, expiring on February 24, 2029. Footnotes explain multiple restricted stock unit grants from 2021 through 2025, each vesting over two years in 50% annual installments.
Trulieve Cannabis Corp. is making a planned change in its top accounting role. The company has given Chief Accounting Officer Joy Malivuk notice that her employment will be terminated without cause, with her last day on May 28, 2026 after a 90‑day notice period. She will continue to receive her regular salary and benefits until that date and, afterward, will receive accrued salary and any earned but unpaid annual bonus for the prior fiscal year, plus severance, COBRA subsidies and accelerated vesting of equity awards as described in her employment agreement, subject to a release and other conditions.
Effective February 28, 2026, Trulieve has appointed Brett Walsh as Chief Accounting Officer and principal accounting officer. Under a new employment agreement effective March 5, 2026, he will receive a $245,000 annual base salary, be eligible for an annual bonus targeted at 20% of base salary for fiscal 2025 and 35% starting in fiscal 2026, and participate in equity and benefit plans consistent with senior management. The agreement also provides defined severance, COBRA coverage and equity vesting protections if he is terminated without cause or resigns for good reason, including enhanced benefits following a change of control.
Trulieve Cannabis Corp. files its annual report outlining a large, vertically integrated U.S. cannabis platform operating 233 dispensaries and 15 cultivation/processing facilities across nine states, anchored in Florida, Pennsylvania, and Arizona. The company emphasizes branded retail, vertical integration, and heavy investment in technology, quality, and customer programs.
Recent developments include conditional approval for a medical cannabis dispensing license in Texas and significant balance sheet activity. Trulieve fully redeemed $368.0 million of 8.0% Senior Secured Notes due 2026 and repaid a $15.8 million mortgage, funded in part by new 10.5% Senior Secured Notes due 2030 totaling $200.0 million. The report devotes extensive discussion to U.S. federal illegality, potential rescheduling of cannabis to Schedule III, banking constraints, taxation, and detailed state-by-state regulation, highlighting ongoing legal, competitive, and operational risks.
Trulieve Cannabis Corp. reported largely stable 2025 results, pairing flat revenue with strong profitability metrics and cash generation. Full-year revenue was $1.2 billion, with 94% from retail, and GAAP gross profit reached $711 million for a 60% gross margin.
The company posted a 2025 GAAP net loss attributable to common shareholders of $116 million, while adjusted net loss narrowed to $27 million. Adjusted EBITDA hit a record $427 million, or 36% of revenue. Cash flow from operations was a record $273 million, and free cash flow was $229 million, supporting year-end cash of $256 million.
In the fourth quarter, revenue was $293 million, GAAP gross profit $175 million with a 60% margin, GAAP net loss $43 million, and adjusted EBITDA $105 million (36% margin). The company redeemed $368 million of 2026 notes, repaid a $15.8 million mortgage, and issued $140 million of 2030 notes, ending 2025 with $232 million of debt at a 9.4% rate.
Operationally, Trulieve sold a record 50.1 million branded units, grew its rewards program to 915,000 members, and finished with 233–234 dispensaries and over four million square feet of cultivation and processing capacity. It received conditional approval for a dispensing license in Texas and continues to challenge U.S. tax treatment under Section 280E, with an $668 million uncertain tax position liability; management notes that without 280E, both Q4 and full-year 2025 net income would have been positive.
Trulieve Cannabis Corp. reported executive compensation changes. Effective January 1, 2026, the Compensation Committee raised CEO Kim Rivers’ base salary from $850,000 to $900,000. Chief Production Officer Kyle Landrum’s base salary increased from $350,000 to $375,000, and Chief Technology Officer Nilyum Jhala’s salary also rose from $350,000 to $375,000.
For additional recognition of 2025 performance, Mr. Landrum received an extra 2025 bonus of $25,000, and Mr. Jhala received an extra 2025 bonus of $50,000 for services rendered.